IMAX heads into its Q1 2026 earnings print today with a compelling contradiction: the chief executive has sold more than $13 million of stock this month, yet the Street's bull camp is intact and short sellers have been slowly covering.
CEO Richard Gelfond has been selling every week since early April. The transactions span nine separate trading sessions, from April 2 through April 27, totalling roughly 365,000 shares at prices clustered between $37 and $40. The aggregate proceeds come to approximately $13.7 million. Director Kevin Douglas trimmed a further $1.6 million in March at similar levels. Neither seller is leaving: Gelfond's liquidations are modest relative to overall insider holdings, and the stock has held the $37 range throughout. But the consistency of the selling — eight consecutive weeks with no corresponding buying from any insider — is the most notable positioning signal into today's numbers.
Short interest tells a less panicked story. At roughly 11% of the free float, the short book is real but not extreme — and it has been shrinking. Short interest has fallen about 14% over the past month, from a peak near 7 million shares in mid-March to just under 5.9 million now. The borrow market remains relaxed: cost to borrow is under 0.5%, and availability is comfortably in the normal range. The ORTEX short score of 66 places the stock in the elevated-but-not-extreme zone. Days to cover was 6.1 on the most recent FINRA filing — meaningful, but the trend is compressing, not expanding.
Options positioning is more neutral than the headline put/call ratio suggests. The PCR of 4.18 sounds alarming in isolation, but it is almost exactly in line with its 20-day average of 4.14. The z-score is near zero. This is a structurally put-heavy name — the 52-week range runs from 0.18 to 9.13 — and the current reading is unremarkable within that context. Options traders are not pricing in a specific directional move; the positioning is stable rather than charged.
The Street has not flinched. The analyst consensus remains solidly constructive. Mean price target is $45.09 against a last close of $37.24 — roughly 21% implied upside. Seaport Global raised its target to $45 from $43 in early April. Wedbush and Rosenblatt both reiterated Buy-equivalent ratings last week, holding targets at $46 and $47 respectively. Goldman Sachs, the sole notable Neutral, lifted its target to $41 from $37 in late February. The bull case centres on IMAX's premium positioning, content pipeline, and steady cash generation — estimated free operating cash flow approaching $136 million on roughly $441 million in revenue. The bear case focuses on China, where regulatory pressure on Hollywood content creates structural uncertainty for a market that has historically driven a large share of IMAX's box office. EV/EBITDA is running around 11.3x, a modest multiple for a high-quality exhibition franchise, and EPS growth momentum over the next 12 months ranks in the 80th percentile of the universe.
Among peers, TKO slipped 1.4% on the week while CNK added 1.7%. IMAX's own 2.8% weekly gain sits comfortably between those extremes — consistent with a stock that is consolidating rather than breaking out. The biggest institutional holder, Kevin Douglas, trimmed his 13.6% stake in March but remains the dominant single name on the cap table, followed by Orbis at 9.5% and Nomura at 7.9%.
With earnings due today after the close, the most recent comparable print — February 25 — produced a 13.4% one-day jump and an 11.8% five-day gain. Whether the China exposure has stabilised, and whether the pipeline of premium content holds through the summer, is the question that will set the tone beyond today's number.
See the live data behind this article on ORTEX.
Open IMAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
